{"name":"Robert Wesolowski","slug":"robert-wesolowski","ticker":"","exchange":"","domain":"","description":"Robert Wesolowski is a biotech company focused on developing innovative vaccines, particularly in the early stages of clinical trials. The company has two key drug candidates in Phase 1 trials, both targeting HER-2 positive cancers.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNUGRxa0xCS21aVm1rbUlGS1FTU2pHQ1lhMEFoLVFkTE1ESnJfRmZZWWdaSk9TLTlSTmlxWmpmVHN0blJoX3M5Z0I3bkJzcThpT2pJZXJlWWktTE5MeFY3emxER25xR0tzUDhoVGpuNnV2Q2dxLWRXbmFzZGxwZ25nT2t5QXRxV2UyOGFzbWtrdV91M0NFTFZrRXNCaERPdF92LUFjVkF3?oc=5","date":"2024-11-04","type":"pipeline","source":"OncLive","summary":"BXQ-350 Is Well Tolerated, Shows Clinical Activity in Advanced Solid Tumors - OncLive","headline":"BXQ-350 Is Well Tolerated, Shows Clinical Activity in Advanced Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9PVE81dHJ5eUFjcW1OWVc5NmNGcjhyc3E3ZllGU0UyQXRxdnNLM3V4dXByQktJdWhVbEt0ZjhWTjJkVVI4NEROeTROQVhTTEFTT3BkR3g5dGFnODBaa21J?oc=5","date":"2023-05-12","type":"trial","source":"Nature","summary":"Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors - Nature","headline":"Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients wit","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}